Aldactone: Effective Potassium-Sparing Diuretic Therapy
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $56.76 (0%) | 🛒 Add to cart |
| 90 | $0.89 | $85.14 $79.98 (6%) | 🛒 Add to cart |
| 120 | $0.87 | $113.52 $104.06 (8%) | 🛒 Add to cart |
| 180 | $0.85 | $170.28 $152.22 (11%) | 🛒 Add to cart |
| 270 | $0.82 | $255.42 $222.74 (13%) | 🛒 Add to cart |
| 360 | $0.82
Best per pill | $340.56 $296.70 (13%) | 🛒 Add to cart |
Aldactone (spironolactone) is a prescription medication belonging to the class of potassium-sparing diuretics. It functions as a competitive antagonist of aldosterone, primarily acting on the distal renal tubules to promote sodium and water excretion while conserving potassium. This mechanism makes it particularly valuable in managing conditions associated with hyperaldosteronism, including essential hypertension, edematous states, and primary hyperaldosteronism. Its unique pharmacological profile distinguishes it from thiazide and loop diuretics, offering clinicians a targeted approach to fluid and electrolyte balance.
Features
- Active ingredient: Spironolactone
- Drug class: Potassium-sparing diuretic/aldosterone antagonist
- Available formulations: 25mg, 50mg, and 100mg tablets
- Bioavailability: Approximately 90% following oral administration
- Protein binding: More than 90% to plasma proteins
- Metabolism: Hepatic, via CYP3A4 to active metabolites (including canrenone)
- Elimination half-life: 1.3-2 hours for spironolactone; 16-23 hours for active metabolites
- Excretion: Primarily renal (42-56%) and biliary (14-46%)
Benefits
- Effectively reduces edema and fluid retention in congestive heart failure, cirrhosis, and nephrotic syndrome
- Provides antihypertensive effects through aldosterone antagonism and reduced vascular resistance
- Maintains potassium homeostasis, reducing the risk of hypokalemia commonly associated with other diuretics
- Demonstrates anti-androgenic properties beneficial in managing hirsutism and acne in polycystic ovary syndrome
- Offers cardioprotective effects in heart failure by mitigating aldosterone-mediated myocardial fibrosis
- Provides diagnostic and therapeutic utility in primary hyperaldosteronism (Conn’s syndrome)
Common use
Aldactone is primarily indicated for the treatment of essential hypertension, often as part of combination therapy when other antihypertensives prove insufficient. It is extensively used in managing edema associated with congestive heart failure, hepatic cirrhosis with ascites, and nephrotic syndrome. The medication is particularly valuable in cases where potassium conservation is clinically important or when thiazide-induced hypokalemia requires management. Off-label applications include treatment of hirsutism in women, acne vulgaris, and female pattern hair loss due to its anti-androgenic properties. In endocrinology, it serves both diagnostic and therapeutic roles in primary hyperaldosteronism.
Dosage and direction
Dosage must be individualized based on therapeutic response and clinical parameters. For hypertension, initial dosing typically ranges from 50-100mg daily, either as a single dose or divided doses, with maintenance doses of 25-200mg daily. For edematous conditions, initial doses of 100mg daily are common, titrated to response, with maximum recommended doses of 200mg daily. In primary hyperaldosteronism, doses may range from 100-400mg daily during diagnostic testing and 100-400mg daily for maintenance therapy. Administration with meals enhances bioavailability. Regular monitoring of serum electrolytes, particularly potassium, is essential during dosage titration and maintenance therapy.
Precautions
Patients should be monitored for hyperkalemia, particularly those with renal impairment, diabetes, or concomitant use of potassium supplements or other potassium-sparing agents. Regular assessment of renal function and electrolytes is mandatory, especially during initiation and dosage adjustments. Caution is advised in patients with hepatic impairment due to potential electrolyte disturbances and altered drug metabolism. Elderly patients may require dosage adjustments due to age-related declines in renal function. Patients should be advised to avoid potassium-rich foods and salt substitutes containing potassium. Breastfeeding is not recommended due to secretion in human milk.
Contraindications
Aldactone is contraindicated in patients with anuria, acute renal insufficiency, significant renal impairment (creatinine clearance <30 mL/min), or hyperkalemia. Additional contraindications include Addison’s disease and concomitant use with eplerenone. Hypersensitivity to spironolactone or any component of the formulation prohibits use. The medication is contraindicated in patients with demonstrated hypersensitivity to thiazide diuretics or other sulfonamide-derived drugs due to potential cross-reactivity.
Possible side effect
Common adverse reactions include hyperkalemia (particularly in patients with renal impairment), gynecomastia (dose-dependent, occurring in 10-15% of male patients), menstrual irregularities, and gastrointestinal disturbances such as nausea and vomiting. Less frequent side effects include drowsiness, lethargy, headache, rash, and postural hypotension. Rare but serious adverse effects include severe hyperkalemia leading to cardiac arrhythmias, hyponatremia, hepatotoxicity, and Stevens-Johnson syndrome. Endocrine effects may include impotence, decreased libido, and hirsutism. Most side effects are dose-dependent and reversible upon discontinuation.
Drug interaction
Significant interactions occur with ACE inhibitors, angiotensin II receptor blockers, and other potassium-sparing diuretics, increasing hyperkalemia risk. NSAIDs may reduce diuretic and antihypertensive effects while increasing nephrotoxicity risk. Digoxin clearance may be altered, requiring monitoring of digoxin levels. Spironolactone may enhance the effects of other antihypertensives, necessitating dosage adjustments. CYP3A4 inhibitors (ketoconazole, erythromycin) may increase spironolactone concentrations. The medication may interfere with assays for digoxin, leading to falsely elevated readings. Lithium excretion may be reduced, increasing lithium toxicity risk.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Patients should not double the dose to make up for a missed administration. Consistent daily administration is important for maintaining therapeutic effects, particularly in hypertension management. Healthcare providers should educate patients about the importance of adherence to prescribed dosing schedules and develop strategies to minimize missed doses, especially in elderly patients or those with complex medication regimens.
Overdose
Aldactone overdose primarily manifests as electrolyte disturbances, particularly hyperkalemia and hyponatremia, which may lead to cardiac arrhythmias, neurological symptoms, and gastrointestinal disturbances. Symptoms may include drowsiness, confusion, nausea, vomiting, dizziness, and diarrhea. Severe hyperkalemia may present with muscle weakness, flaccid paralysis, and life-threatening cardiac arrhythmias. Management involves immediate discontinuation of the medication, gastric lavage if ingestion was recent, and aggressive management of electrolyte abnormalities. Hemodialysis may be effective in removing active metabolites. Cardiac monitoring is essential in cases of significant overdose.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in the original container with the lid tightly closed. Protect from light and excessive moisture. Keep out of reach of children and pets. Do not store in bathroom cabinets where humidity levels may fluctuate. Discard any medication that has expired or shows signs of physical deterioration. Proper disposal methods should be followed according to local regulations, preferably through medication take-back programs rather than flushing or household trash disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Aldactone is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient responses may vary, and therapeutic decisions should be based on comprehensive clinical assessment. Patients should not initiate, discontinue, or modify therapy without consulting their healthcare provider. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical studies demonstrate Aldactone’s efficacy in heart failure management, with the RALES trial showing 30% mortality reduction when added to standard therapy in severe heart failure patients. In hypertension management, multiple studies confirm its effectiveness as monotherapy and in combination regimens, particularly in low-renin hypertensive populations. Dermatological applications show significant improvement in hirsutism scores and acne severity in numerous randomized controlled trials. Patient satisfaction surveys indicate high tolerability when properly monitored, though gynecomastia remains a significant concern in male patients requiring long-term therapy at higher doses.